SynthesisFrontiers in pharmacology2025
A systematic review with meta-analysis on the efficacy of 0.01% atropine eyedrops in preventing myopia progression in worldwide children's populations.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Negligible Rebound in Myopia Progression Following Cessation of Treatment with 0.01% Atropine for 3 years: Year-4 Results from the CHAMP Phase 3 Clinical Trial.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Trial
- Effect of 0.01% Atropine on Choroidal Thickness and Ocular Growth in Pre-myopic Children.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Trial
- Low-Concentration Atropine for Myopia Management: Recent Evidence and Clinical Implications.Ophthalmology and therapy · 2026Review
- Italian consensus on pediatric myopia: findings from a three-round modified delphi study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Beyond mild myopia: a pilot randomized trial of 0.01% atropine in school-aged children with myopia ≤ -4.50 D.Japanese journal of ophthalmology · 2026Article
- Low-Concentration Atropine (0.01%, 0.025%, 0.05%) for Myopia Progression in Children: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- Myopic Progression Associated with COVID-19 Pandemic in Korean Children with Myopia Using 0.01% Atropine Eyedrops.Life (Basel, Switzerland) · 2026Article
- Atropine Eye Drops in Childhood Myopia Control: A Review.International journal of medical sciences · 2026Review
- Effectiveness of Low-Dose Atropine (0.01% to 0.05%) in Reducing Myopia Progression: A Systematic Review and Meta-Analysis.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Atropine eyedrops have long been used off-label to prevent myopia progression in children, and many clinical trials have been published on this topic in the past 30 years. Trials initially tested doses ranging from 0.01% to 1%, but more recently, the interest has turned to low doses, mainly 0.01%. Moreover, the first studies were carried out in Asian populations, but the number of trials conducted in other geographical areas has rapidly increased from 2020 onward. This meta-analysis was aimed at summarizing the evidence on the efficacy of 0.01% atropine eyedrops on the reduction of myopia progression, also comparing study findings from different parts of the world. Methods: Data were obtained from PubMed, Scopus and Web of Science databases from 1 January 1 2020 to 31 July 2024. Randomized controlled trials involving children receiving 0.01% atropine eyedrops for at least 1 year were included. Heterogeneity was quantified by Q, H, and I2 statistics, and a meta-analysis was performed using a random effect model. The risk for bias was assessed using the Cochrane Collaboration (Chapter 6) aspects of bias scale. Results and discussion: The primary outcomes were the differences in spherical equivalent refractive errors and axial length at baseline and after 12 months of treatment with 0.01% atropine eyedrops or placebo. Eleven studies involving 2,046 children (1,172 receiving 0.01% atropine eyedrops and 874 receiving placebo) were included. Atropine was significantly more effective than placebo, with an average reduction of 0.16/year (95% CI: 0.11-0.22) and -0.07/year (95% CI: -0.09 to -0.05) in spherical equivalent refractive errors and axial length, respectively. The efficacy of 0.01% atropine eyedrops vs. placebo was maintained in a subpopulation of subjects after 24 months of treatment. We found no difference in atropine efficacy between Southeast Asian populations (1,063 children, 52%) and populations in various other countries (983 children, 48%).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.